Semax

Overview

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to an analogue of the 4-10 fragment of adrenocorticotropic hormone (ACTH) with a proline-glycine-proline tripeptide appended to the C-terminus in place of the native ACTH(11-39) sequence. It was developed during the 1980s by a research group led by Ivan Ashmarin at Moscow State University, working with the Institute of Molecular Genetics of the Russian Academy of Sciences, as part of a broader Soviet-era research programme investigating fragments of pituitary and adrenal hormones for effects on the central nervous system that were dissociated from their classical endocrine functions.

The starting point for this work was a long-standing observation in neuroendocrinology: proteolytic fragments of ACTH, and in particular the 4-10 sequence, retained behavioural and cognitive effects in animal models even though this fragment lacks the structural elements required to bind melanocortin receptors and stimulate adrenal steroidogenesis. In other words, ACTH(4-10) appeared to be neurotropic without being a hormone in the conventional sense. Ashmarin's group set out to stabilise this fragment against rapid enzymatic degradation — the native heptapeptide is cleaved within minutes by aminopeptidases and other plasma proteases — while preserving or enhancing the neurotropic activity. The addition of the Pro-Gly-Pro tripeptide at the C-terminus was the key modification: this small addition substantially increases resistance to enzymatic breakdown without introducing hormonal activity of its own.

The resulting compound, Semax, was characterised by its developers as a non-hormonal, non-opioid neuropeptide: it does not measurably raise cortisol, does not act as an opioid receptor ligand (unlike some other ACTH- and MSH-related fragments that show incidental affinity for opioid receptors), and shows no meaningful activity at classical corticotropin receptors. Delivery was another distinguishing design choice. Because Semax is a peptide, oral bioavailability is negligible, but rather than pursuing injectable formulations — the dominant route for most of the Khavinson-family and other Russian regulatory peptides — Ashmarin's group and subsequent Russian pharmaceutical development settled on intranasal delivery as the primary route, exploiting direct or near-direct access from the nasal mucosa to the central nervous system via olfactory and trigeminal pathways, largely bypassing first-pass hepatic metabolism and reducing systemic peptidase exposure relative to oral or even some parenteral routes.

Semax was subsequently registered as a medicine in Russia (marketed under names including Semax and later a 1% intranasal solution) for indications spanning acute ischaemic stroke, transient ischaemic attack, and a range of cognitive and neurasthenic disorders, and has been in clinical use there for several decades. It has never been granted a marketing authorisation by the MHRA, EMA or FDA, and independent replication of the Russian clinical and mechanistic literature outside the former Soviet research network remains comparatively limited.

Interest in Semax outside Russia has grown alongside the broader online nootropics community, where it is frequently discussed together with its structural cousin Selank and with the Khavinson short-peptide family, including Pinealon. This interest sits somewhat apart from the compound's original clinical registration: Western enthusiasm has often centred on unlicensed self-administration for cognitive enhancement, a use case quite different from the medically supervised stroke-rehabilitation and neurological-disorder contexts in which the Russian clinical literature was generated. This page summarises what has been published on Semax's proposed mechanisms, the research and regulatory history, the available safety information, and how the compound is treated under UK law. Nothing here is medical advice, and the material is intended for research and educational purposes only.

Mechanism of action

The most consistently reported mechanistic finding for Semax is upregulation of brain-derived neurotrophic factor (BDNF) expression in the central nervous system, alongside effects on nerve growth factor (NGF). In rodent studies, intranasal Semax increases BDNF mRNA and protein levels in the hippocampus and frontal cortex within hours of administration, and this neurotrophic signal has become the leading candidate explanation for the peptide's reported effects on learning, memory consolidation and neuronal resilience. Because BDNF supports synaptic plasticity, neuronal survival and long-term potentiation, a peptide capable of transiently but reliably raising its expression in specific brain regions is mechanistically plausible as both a cognitive-enhancement and a neuroprotective agent, and this has shaped the bulk of subsequent Russian mechanistic work on the compound.

A second body of work addresses direct neuroprotection in models of cerebral ischaemia and hypoxia. Semax has been reported to reduce infarct volume, limit neuronal apoptosis, and improve neurological and behavioural outcome scores in rodent models of focal cerebral ischaemia, typically using middle cerebral artery occlusion paradigms. Proposed contributing mechanisms include attenuation of excitotoxic glutamate signalling, modulation of pro- and anti-apoptotic protein expression (including effects on caspase activity), and reduction of markers of oxidative stress in penumbral tissue. Some of this work has also examined effects on microglial activation and post-ischaemic inflammatory markers, with several groups reporting a shift toward a less pro-inflammatory microglial phenotype following Semax administration, although this strand of the literature is less extensively replicated than the BDNF and infarct-volume findings.

Semax has also been reported to modulate dopaminergic and serotonergic signalling. Russian pharmacological studies describe changes in dopamine and serotonin turnover in specific brain regions following Semax administration, along with effects on monoamine oxidase activity, and these findings have been used to rationalise reported anxiolytic and mood-related effects in both animal behavioural assays and the Russian clinical literature on neurasthenic and asthenic-depressive states. The proposed mechanism is not receptor agonism in the classical sense — Semax is not described as binding directly to dopamine or serotonin receptors with meaningful affinity — but rather an upstream modulatory effect on monoaminergic tone, plausibly downstream of, or parallel to, the neurotrophic signalling described above. The precise molecular target responsible for this modulation has not been definitively identified.

Delivery is mechanistically inseparable from Semax's pharmacology. Intranasal administration is understood to allow at least partial direct access to the central nervous system via the olfactory epithelium and associated perivascular and perineural pathways, avoiding much of the peripheral proteolytic degradation that would be expected with oral dosing and reducing systemic exposure relative to parenteral routes. Electrophysiological work in rodents has reported that Semax influences hippocampal long-term potentiation (LTP), the cellular correlate most closely associated with learning and memory formation, with several studies describing enhanced LTP induction or maintenance following peptide administration. Taken together with the reported effects on oxidative-stress markers — including modulation of superoxide dismutase and catalase activity in cortical and hippocampal tissue — the overall mechanistic picture presented in the Russian literature is of a peptide that acts as a broad neurotrophic and neuroprotective modulator rather than a single-receptor pharmacological agent, which is both a strength (multiple converging lines of preclinical evidence) and a limitation (a mechanism this diffuse is harder to pin down and independently falsify than a single well-defined receptor interaction).

Research history

Semax originates from the ACTH-fragment research programme led by Ivan Petrovich Ashmarin at the Department of Human and Animal Physiology, Moscow State University, during the 1980s, working in collaboration with what became the Institute of Molecular Genetics of the Russian Academy of Sciences. The design rationale — stabilising the neurotropic ACTH(4-10) fragment against rapid proteolysis while stripping away hormonal activity — was itself built on earlier Soviet and Western neuroendocrinology describing dissociated behavioural effects of ACTH fragments in the 1960s and 1970s. Following synthesis and initial pharmacological characterisation, Semax progressed through Soviet and then Russian pharmaceutical development and clinical testing over the following two decades.

Clinical work in Russia has focused predominantly on acute ischaemic stroke and transient ischaemic attack, where Semax has been studied as an adjunct to standard care, with reported improvements in neurological recovery scores and reduced mortality in some open-label and comparator-controlled series. A parallel clinical literature addresses cognitive impairment, optic nerve disorders, attention-deficit presentations in children, and asthenic and neurotic conditions, reflecting the broad neurotropic framing under which the compound was developed. Semax received Russian state registration as a medicine and has been manufactured and marketed there for several decades, principally as a 0.1% or 1% intranasal solution, under conditions of continuing clinical use rather than a single pivotal registration trial in the sense familiar from EMA or FDA pathways.

The published literature on Semax is overwhelmingly Russian in origin and, for the older clinical material especially, predominantly Russian-language, which has limited both accessibility and independent scrutiny outside the former Soviet research network. Mechanistic work from the 2000s and 2010s — much of it associated with researchers including Myasoedov, Levitskaya, Kolomin, Dolotov and others working in the same institutional lineage as the original Ashmarin group — has substantially deepened the case for BDNF- and NGF-mediated effects and produced more internationally accessible publications in English-language pharmacology and neuroscience journals. Independent replication by research groups outside Russia remains limited, and no phase II or III trial meeting contemporary EMA, MHRA or FDA standards has been conducted or registered for Semax, which is the principal reason the compound has not progressed toward Western regulatory recognition despite its multi-decade clinical history in its country of origin.

A useful way to frame the state of the evidence is by tier. At the strongest tier sits a reasonably large and internally consistent body of rodent and cell-culture work on BDNF/NGF upregulation, published across several research groups within the same broad institutional lineage and spanning more than two decades, which is the closest the Semax literature comes to a converging, semi-independent evidence base. At a weaker tier sits the ischaemia and stroke-model work, which is mechanistically plausible and broadly consistent across studies but drawn from a narrower set of research groups. At the weakest tier sits the human clinical literature, which despite decades of accumulated case series and open-label cohorts has not produced a trial meeting the randomisation, blinding and pre-registration standards that would allow confident quantification of effect size in a Western regulatory sense. Readers should weight claims about Semax accordingly, treating the animal mechanistic work as reasonably solid and the human efficacy claims as suggestive rather than established.

Summarised studies